✦ LIBER ✦

4–57 A Phase II Trial of Pemetrexed in Advanced Breast Cancer: Clinical Response and Association With Molecular Target Expression

✍ Scribed by Budman, D.R.

Book ID: 123256153
Publisher: Elsevier Science
Year: 2007
Tongue: English
Weight: 75 KB
Volume: 17
Category: Article
ISSN: 1043-321X
DOI: 10.1016/S1043-321X(07)80173-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

CA125 response and disease stabilisation

CA125 response and disease stabilisation are associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer

✍ Smyth, J.F.; Bowman, A.; Gabra, H.; Lessels, A.; Stewart, M.; Young, A.; Langdon 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 356 KB

Pemetrexed Versus Pemetrexed and Carbopl

Pemetrexed Versus Pemetrexed and Carboplatin As Second-Line Chemotherapy in Advanced Non-Small-Cell Lung Cancer: Results of the GOIRC 02-2006 Randomized Phase II Study and Pooled Analysis With the NVALT7 Trial

✍ Ardizzoni, A.; Tiseo, M.; Boni, L.; Vincent, A. D.; Passalacqua, R.; Buti, S.; A 📂 Article 📅 2012 🏛 American Society of Clinical Oncology 🌐 English ⚖ 200 KB

Clinical and Immunologic Responses of HL

Clinical and Immunologic Responses of HLA-A3+ Breast Cancer Patients Vaccinated with the HER2/neu-Derived Peptide Vaccine, E75, in a Phase I/II Clinical Trial

✍ Ritesh Patil; Guy T. Clifton; Jarrod P. Holmes; Asna Amin; Mark G. Carmichael; J 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 728 KB

Phase II study of pemetrexed disodium, a

Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma : A study of the national cancer institute of Canada clinical trials group

✍ Frances A. Shepherd; Janet Dancey; Andrew Arnold; Alan Neville; James Rusthoven; 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 90 KB 👁 3 views

## Background: Pemetrexed disodium (alimta [eli lilly and company, indianapolis, in], ly231514, multitargeted antifolate) is a new multitargeted antifolate agent that inhibits multiple enzymes in the folate pathway. phase ii trials showed single-agent response rates of 16% and 23% in untreated pati

PO-63 Combining chemotherapy and low-mol

PO-63 Combining chemotherapy and low-molecular-weight heparin for the treatment of advanced breast cancer: results on clinical response, transforming growth factor-beta 1 and fibrin monomer in a phase II study

✍ N. Seeholzer; B. Th¨urlimann; D. K¨oberle; D. Hess; W. Korte 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 55 KB

Epitope-specific immunotherapy of rheuma

Epitope-specific immunotherapy of rheumatoid arthritis: Clinical responsiveness occurs with immune deviation and relies on the expression of a cluster of molecules associated with T cell tolerance in a double-blind, placebo-controlled, pilot phase II trial

✍ Eva C. Koffeman; Mark Genovese; Diane Amox; Elissa Keogh; Ernesto Santana; Eric 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 192 KB 👁 2 views